ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. The company is also developing Avacopan for the treatment of patients with complement 3 glomerulopathy and hidradenitis suppurativa. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis. Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-210-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.88 million
Profitability
Miscellaneous
Employees76
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx Inc (NASDAQ:CCXI) posted its earnings results on Monday, March, 11th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.06. The biopharmaceutical company earned $9.33 million during the quarter, compared to analysts' expectations of $9.54 million. ChemoCentryx had a negative net margin of 88.55% and a negative return on equity of 167.57%. View ChemoCentryx's Earnings History.
When is ChemoCentryx's next earnings date?
What price target have analysts set for CCXI?
8 brokers have issued 1 year price targets for ChemoCentryx's stock. Their predictions range from $15.00 to $22.00. On average, they expect ChemoCentryx's share price to reach $19.1667 in the next year. This suggests a possible upside of 58.0% from the stock's current price. View Analyst Price Targets for ChemoCentryx.
What is the consensus analysts' recommendation for ChemoCentryx?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.
Has ChemoCentryx been receiving favorable news coverage?
Press coverage about CCXI stock has been trending positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ChemoCentryx earned a daily sentiment score of 2.4 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Insmed (INSM), Arena Pharmaceuticals (ARNA), Portola Pharmaceuticals (PTLA), PTC Therapeutics (PTCT), Uniqure (QURE), The Medicines (MDCO), AnaptysBio (ANAB) and Endocyte (ECYT).
What other stocks do shareholders of ChemoCentryx own?
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)
- Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)
- Dr. Rajinder Singh, Sr. VP of Research (Age 52)
- Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)
- Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58)
Who are ChemoCentryx's major shareholders?
ChemoCentryx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Meeder Asset Management Inc. (0.01%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Plc Glaxosmithkline, Rajinder Singh, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.
Which major investors are buying ChemoCentryx stock?
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $12.13.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $700.22 million and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.
What is ChemoCentryx's official website?
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
